{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T07:57:35Z","timestamp":1794211055639,"version":"4.8.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,6]],"date-time":"2014-11-06T00:00:00Z","timestamp":1415232000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["cancercell.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.ccell.2014.11.001","type":"journal-article","created":{"date-parts":[[2014,12,11]],"date-time":"2014-12-11T13:37:44Z","timestamp":1418305064000},"page":"138-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":175,"title":["Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies"],"prefix":"10.1016","volume":"27","author":[{"given":"Ann\u00a0L.","family":"White","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.T.\u00a0Claude","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth\u00a0R.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Willoughby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.\u00a0Ian","family":"Mockridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Roghanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine\u00a0A.","family":"Penfold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven\u00a0G.","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Dodhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta\u00a0E.","family":"Polak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth\u00a0A.","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael\u00a0R.","family":"Ardern-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.\u00a0Sjef","family":"Verbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter\u00a0W.M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aymen","family":"Al-Shamkhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark\u00a0S.","family":"Cragg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen\u00a0A.","family":"Beers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin\u00a0J.","family":"Glennie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2014.11.001_bib1","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1200\/JCO.2008.21.3017","article-title":"Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin\u2019s lymphoma","volume":"27","author":"Advani","year":"2009","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2014.11.001_bib2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ni792","article-title":"The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells","volume":"3","author":"Ahonen","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ccell.2014.11.001_bib3","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1021\/bi8022174","article-title":"Interchain disulfide bonding in human IgG2 antibodies probed by site-directed mutagenesis","volume":"48","author":"Allen","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.ccell.2014.11.001_bib4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0161-5890(93)90432-B","article-title":"A single amino acid substitution abolishes the heterogeneity of chimeric mouse\/human (IgG4) antibody","volume":"30","author":"Angal","year":"1993","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ccell.2014.11.001_bib5","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1158\/2326-6066.CIR-14-0154","article-title":"Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma","volume":"2","author":"Bajor","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ccell.2014.11.001_bib6","first-page":"127","article-title":"IgG2 subclass restriction of antibody to pneumococcal polysaccharides","volume":"63","author":"Barrett","year":"1986","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ccell.2014.11.001_bib7","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.4049\/jimmunol.1302461","article-title":"Cell contact-dependent priming and Fc interaction with CD32+ immune cells contribute to the TGN1412-triggered cytokine response","volume":"192","author":"Bartholomaeus","year":"2014","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ccell.2014.11.001_bib8","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ccell.2014.11.001_bib9","doi-asserted-by":"crossref","first-page":"6286","DOI":"10.1158\/1078-0432.CCR-13-1320","article-title":"A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma","volume":"19","author":"Beatty","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2014.11.001_bib10","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.4049\/jimmunol.1101194","article-title":"The inhibiting Fc receptor for IgG, Fc\u03b3RIIB, is a modifier of autoimmune susceptibility","volume":"187","author":"Boross","year":"2011","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ccell.2014.11.001_bib11","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2014.11.001_bib12","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses","volume":"113","author":"Bruhns","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2014.11.001_bib13","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1084\/jem.20130573","article-title":"Activating Fc \u03b3 receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies","volume":"210","author":"Bulliard","year":"2013","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ccell.2014.11.001_bib14","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/icb.2014.26","article-title":"OX40 engagement depletes intratumoral Tregs via activating Fc\u03b3Rs, leading to antitumor efficacy","volume":"92","author":"Bulliard","year":"2014","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.ccell.2014.11.001_bib15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/2326-6066.CIR-13-0070","article-title":"Ex\u00a0vivo assays of dendritic cell activation and cytokine profiles as predictors of in\u00a0vivo effects in an anti-human CD40 monoclonal antibody ChiLob 7\/4 phase I trial","volume":"2","author":"Chowdhury","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ccell.2014.11.001_bib16","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1016\/j.molimm.2008.06.027","article-title":"Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies","volume":"45","author":"Chu","year":"2008","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ccell.2014.11.001_bib17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc\u00a0receptors modulate in\u00a0vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2014.11.001_bib18","unstructured":"Drachman, J., Law, C.-L., and Lewis, T. May 2007. Methods of using CD40 binding agents. U.S. patent WO\/2007\/075326."},{"key":"10.1016\/j.ccell.2014.11.001_bib19","doi-asserted-by":"crossref","first-page":"16206","DOI":"10.1074\/jbc.M709988200","article-title":"Structural and functional characterization of disulfide isoforms of the human IgG2 subclass","volume":"283","author":"Dillon","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ccell.2014.11.001_bib20","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ccell.2014.11.001_bib21","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/5505","article-title":"CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help","volume":"5","author":"French","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2014.11.001_bib22","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1182\/blood-2006-11-057216","article-title":"Eradication of lymphoma by CD8 T\u00a0cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation","volume":"109","author":"French","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2014.11.001_bib23","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/0161-5890(91)90011-8","article-title":"Characterization of a new monoclonal anti-Fc gamma RII antibody, AT10, and its incorporation into a bispecific F(ab\u2032)2 derivative for recruitment of cytotoxic effectors","volume":"28","author":"Greenman","year":"1991","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ccell.2014.11.001_bib24","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/elps.200800083","article-title":"Electrophoretic evidence for the presence of structural isoforms specific for the IgG2 isotype","volume":"29","author":"Guo","year":"2008","journal-title":"Electrophoresis"},{"key":"10.1016\/j.ccell.2014.11.001_bib25","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1084\/jem.20052283","article-title":"Antibody isotype-specific engagement of Fcgamma receptors regulates B\u00a0lymphocyte depletion during CD20 immunotherapy","volume":"203","author":"Hamaguchi","year":"2006","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ccell.2014.11.001_bib26","unstructured":"Hanke, T., Trischler, M., and Guntermann, C. September 2009. Encoding a binding molecule specifically binding to a human CD28 molecule; comprising a nucleic acid sequence encoding a VH region and a nucleic acid sequence encoding a VL region with CDRs in a human immunoglobulin framework. U.S. patent US7585960."},{"key":"10.1016\/j.ccell.2014.11.001_bib27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nm1183","article-title":"Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in\u00a0vivo","volume":"11","author":"Hanks","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2014.11.001_bib28","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2014.11.001_bib29","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood-2010-08-301945","article-title":"CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies","volume":"117","author":"Kohrt","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2014.11.001_bib30","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1172\/JCI61226","article-title":"Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer","volume":"122","author":"Kohrt","year":"2012","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ccell.2014.11.001_bib31","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1172\/JCI73014","article-title":"Targeting CD137 enhances the efficacy of cetuximab","volume":"124","author":"Kohrt","year":"2014","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ccell.2014.11.001_bib32","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1158\/1078-0432.CCR-06-1726","article-title":"Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines","volume":"13","author":"Kurai","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2014.11.001_bib33","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1126\/science.1206954","article-title":"Inhibitory Fc\u03b3 receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies","volume":"333","author":"Li","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ccell.2014.11.001_bib34","doi-asserted-by":"crossref","first-page":"10966","DOI":"10.1073\/pnas.1208698109","article-title":"Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fc\u03b3 receptor engagement","volume":"109","author":"Li","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccell.2014.11.001_bib35","doi-asserted-by":"crossref","first-page":"19501","DOI":"10.1073\/pnas.1319502110","article-title":"Antitumor activities of agonistic anti-TNFR antibodies require differential Fc\u03b3RIIB coengagement in\u00a0vivo","volume":"110","author":"Li","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccell.2014.11.001_bib36","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/pro.352","article-title":"Mutations within a human IgG2 antibody form distinct and homogeneous disulfide isomers but do not affect Fc gamma receptor or C1q binding","volume":"19","author":"Lightle","year":"2010","journal-title":"Protein Sci."},{"key":"10.1016\/j.ccell.2014.11.001_bib37","doi-asserted-by":"crossref","first-page":"29266","DOI":"10.1074\/jbc.M804787200","article-title":"Human IgG2 antibody disulfide rearrangement in\u00a0vivo","volume":"283","author":"Liu","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ccell.2014.11.001_bib38","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.4049\/jimmunol.1200501","article-title":"Impact of immune\u00a0complex size and glycosylation on IgG binding to human Fc\u03b3Rs","volume":"190","author":"Lux","year":"2013","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ccell.2014.11.001_bib39","doi-asserted-by":"crossref","first-page":"7496","DOI":"10.1021\/bi800576c","article-title":"Disulfide connectivity of human immunoglobulin G2 structural isoforms","volume":"47","author":"Martinez","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.ccell.2014.11.001_bib40","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.coi.2013.01.004","article-title":"The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy","volume":"25","author":"Moran","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ccell.2014.11.001_bib41","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1126\/science.1118948","article-title":"Divergent immunoglobulin g subclass activity through selective Fc receptor binding","volume":"310","author":"Nimmerjahn","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.ccell.2014.11.001_bib42","first-page":"13","article-title":"Translating basic mechanisms of\u00a0IgG effector activity into next generation cancer therapies","volume":"12","author":"Nimmerjahn","year":"2012","journal-title":"Cancer Immun."},{"key":"10.1016\/j.ccell.2014.11.001_bib43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1158\/2326-6066.CIR-13-0152","article-title":"Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer","volume":"2","author":"Richman","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ccell.2014.11.001_bib44","doi-asserted-by":"crossref","first-page":"e64076","DOI":"10.1371\/journal.pone.0064076","article-title":"Three-dimensional structure of the human myeloma IgG2","volume":"8","author":"Ryazantsev","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ccell.2014.11.001_bib45","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.4049\/jimmunol.178.3.1564","article-title":"Combined TLR\/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in\u00a0vivo","volume":"178","author":"Sanchez","year":"2007","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ccell.2014.11.001_bib46","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T\u00a0cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ccell.2014.11.001_bib47","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1126\/science.1241145","article-title":"Antibody therapeutics in cancer","volume":"341","author":"Sliwkowski","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ccell.2014.11.001_bib48","doi-asserted-by":"crossref","first-page":"10914","DOI":"10.1074\/jbc.M112.427583","article-title":"Cysteine-rich domain 1 of CD40 mediates receptor self-assembly","volume":"288","author":"Smulski","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ccell.2014.11.001_bib49","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2014.11.001_bib50","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2014.11.001_bib51","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1084\/jem.20040119","article-title":"The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy","volume":"199","author":"Uchida","year":"2004","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ccell.2014.11.001_bib52","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1158\/1078-0432.CCR-12-2064","article-title":"Agonistic CD40 antibodies and cancer therapy","volume":"19","author":"Vonderheide","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2014.11.001_bib53","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2567.2010.03285.x","article-title":"Ligation of CD11c during vaccination promotes germinal centre induction and robust humoral responses without adjuvant","volume":"131","author":"White","year":"2010","journal-title":"Immunology"},{"key":"10.1016\/j.ccell.2014.11.001_bib54","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.4049\/jimmunol.1101135","article-title":"Interaction with Fc\u03b3RIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody","volume":"187","author":"White","year":"2011","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ccell.2014.11.001_bib55","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00262-013-1398-6","article-title":"Fc\u03b3R\u0399\u0399B controls the potency of agonistic anti-TNFR mAbs","volume":"62","author":"White","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ccell.2014.11.001_bib56","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.4049\/jimmunol.1303204","article-title":"FcR dependence of agonistic CD40 antibody is related to anatomical location and can be overcome by antibody multimerisation","volume":"193","author":"White","year":"2014","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ccell.2014.11.001_bib57","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ccr.2010.11.012","article-title":"An Fc\u03b3 receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells","volume":"19","author":"Wilson","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2014.11.001_bib58","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2014.11.001_bib59","doi-asserted-by":"crossref","first-page":"16194","DOI":"10.1074\/jbc.M709987200","article-title":"Human IgG2 antibodies display disulfide-mediated structural isoforms","volume":"283","author":"Wypych","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ccell.2014.11.001_bib60","doi-asserted-by":"crossref","first-page":"562","DOI":"10.4049\/jimmunol.171.2.562","article-title":"Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics","volume":"171","author":"Xu","year":"2003","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ccell.2014.11.001_bib61","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.4049\/jimmunol.170.6.3134","article-title":"Human IgG2 can form covalent dimers","volume":"170","author":"Yoo","year":"2003","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ccell.2014.11.001_bib62","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1021\/ac902466z","article-title":"Determination of Fab-hinge disulfide connectivity in structural isoforms of a recombinant human immunoglobulin G2 antibody","volume":"82","author":"Zhang","year":"2010","journal-title":"Anal. Chem."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610814004528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610814004528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T16:39:24Z","timestamp":1717605564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610814004528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S1535610814004528"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2014.11.001","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725276419.793503869","asserted-by":"object"}]},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2014.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}